Purpose of the Review <p>With the continued increase in the prevalence of food allergy and its significant associated medical and financial burden, there is a need for safe and effective treatment options for patients. The goal of this review is to summarize published data on the safety and efficacy of peanut sublingual immunotherapy (SLIT) as a potential treatment option for children with food allergy.</p> Recent Findings <p>Peanut SLIT has demonstrated clinically significant desensitization across 2 cohorts of children ages 1–11 years. In a study focused on 1–4-year-old peanut-allergic toddlers, even greater levels of desensitization as well as the potential for 3-month remission has been demonstrated. Small studies have also demonstrated potential efficacy with SLIT for other foods such as milk, hazelnut, and peach.</p> Summary <p>Evidence to date supports SLIT as effective and safe and a potential future treatment option for children with food allergy.</p>